肠道微生物群,肠道屏障功能,以及通过肥胖和葡萄糖耐受性的新陈代谢
Karynne Grutter Lopes1,2,3,4, Maria das Graças Coelho de Souza1,2,4, Fernanda de Azevedo Marques Lopes1
1Postgraduate Program in Clinical and Experimental Physiopathology (Fisclinex), Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-013, Brazil.
Nutrients
|November 13, 2025
概括
肥胖和失糖症与肠道屏障功能障碍有关. 减少肠道性酸酶活性和改变的肠道细菌突出显示了肠道屏障作为代谢障碍的治疗点.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
背景情况:
- 肥胖和失糖症越来越多地与肠道屏障功能障碍和肠道微生物群变化有关.
- 肠道超透性是一种潜在的治疗标,但整合屏障生物标记物,上皮形态和微生物组成的人类数据是有限的.
研究的目的:
- 为了研究瘦,肥胖和肥胖的失糖症患者的肠道屏障功能.
- 为了将肠道屏障生物标志物和形态与代谢参数和肠道微生物群组成相关联.
主要方法:
- 将46名成年人分为精益控制,肥胖正常血糖和肥胖失糖组.
- 测量生物化学标记物 (LPS,LBP),十二指肠组织学,蛋白质表达和酶活性 (IAP).
- 使用16S rRNA基因测序分析便微生物组合 (FMC).
主要成果:
- 十二指甲状腺组形测量没有差异;然而,肠道性酸酶 (IAP) 在肥胖失糖组较低.
- 脂聚糖 (LPS) 和与脂肪性标志物相关联的LPS结合蛋白 (LBP).
- 降低IAP和改变的β-actin表达与代谢功能障碍相关 (BMI,葡萄糖,HbA1c,HOMA-IR).
- 微生物群的多样性是相似的,但特定的种群 (Clostridiales) 在失糖症下降.
结论:
- 降低IAP活性和屏障生物标志物和代谢参数之间的相关性表明肥胖和失糖症的肠道屏障功能障碍.
- 微妙的肠道微生物群变化表明肠道生态与代谢控制之间存在联系.
- 肠道屏障是代谢障碍的一个有前途的治疗点.
相关概念视频
Physiology of Enteric Nervous System and Gut Health
844
The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...
844
Glucose Absorption Into the Small Intestine
34.9K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.9K
Anatomy of the Intestines
86.6K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
86.6K
Bacterial Flora of the Large Intestine
1.5K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.5K
Regulation of Metabolism
11.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230


